US2005282767A1PendingUtilityA1

Inhibitors of epoxide hydrolases for the treatment of hypertension

Assignee: US GOV HEALTH & HUMAN SERVPriority: Feb 18, 1999Filed: Jul 25, 2005Published: Dec 22, 2005
Est. expiryFeb 18, 2019(expired)· nominal 20-yr term from priority
A61K 31/00A61K 31/325A61P 9/12A61K 31/336
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 —R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

Claims

exact text as granted — not AI-modified
1 . A method of treating hypertension in a patient, the method comprising administering to the patient a therapeutically effective amount of a nucleic acid which inhibits epoxide hydrolase (EH) gene expression.  
   
   
       2 . A method of  claim 1 , wherein the nucleic acid is complementary to a portion of a human gene encoding EH.  
   
   
       3 . A method of  claim 1 , wherein the nucleic acid is DNA.  
   
   
       4 . A method of  claim 1 , wherein the nucleic acid is RNA.  
   
   
       5 . A method of  claim 1 , wherein the nucleic acid is modified to increase resistance to nucleases.  
   
   
       6 . A method of delivering a reactive functionality to epoxide hydrolase, said method comprising contacting said epoxide hydrolase with a compound selected from the group consisting of Formula I and of Formula II, wherein 
 (a) compounds of Formula I have the structure                          wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4  is hydrogen, R 2  is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4  is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1  and R 3  are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, and    (b) compounds of Formula II have the structure                          wherein R is alkyl or aryl, the compound is trans- across the epoxide ring, OX is a carbonyl (═O) or hydroxy group (OH) and R′ is a H, alkyl or aryl group,    and further wherein said compound of Formula I or Formula II is derivatized with a reactive functionality.    
   
   
       7 . A method of  claim 6 , wherein the reactive functionality is an alkylating agent or a Michael acceptor  
   
   
       8 . A method of  claim 7 , wherein the alkylating agent is a halogen.  
   
   
       9 . A method of  claim 7 , wherein the alkylating agent is an epoxide.  
   
   
       10 . A method of  claim 6 , wherein said compound of Formula I or Formula II is derivatized with a Michael acceptor.  
   
   
       11 . A method of  claim 6 , wherein said compound is a compound of Formula I.  
   
   
       12 . A method of  claim 6 , wherein said compound is a compound of Formula II.  
   
   
       13 . A method of detecting epoxide hydrolase, said method comprising contacting said epoxide hydrolase with a compound selected from the group consisting of Formula I and of Formula II, wherein 
 (a) compounds of Formula I have the structure                          wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4  is hydrogen, R 2  is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4  is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1  and R 3  are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, and    (b) compounds of Formula II have the structure                          wherein R is alkyl or aryl, the compound is trans- across the epoxide ring, OX is a carbonyl (═O) or hydroxy group (OH) and R′ is a H, alkyl or aryl group, and further wherein said compound of Formula I or Formula II is derivatized with a fluorescent or affinity label.

Join the waitlist — get patent alerts

Track US2005282767A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.